Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GridAI TechnologiesGRDX +1.08%26 EBITDA Margin % is -6,947.37% as of Mar. 2026. GuruFocus rates GRDX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, GridAI Technologies ranks worse than 93.96% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. GridAI Technologies's EBITDA for the
three
months ended in Mar. 2026 was $-2.64 Mil. GridAI Technologies's Revenue for the
three
months ended in Mar. 2026 was $0.04 Mil. Therefore, GridAI Technologies's EBITDA margin for the quarter that ended in Mar. 2026 was -6,947.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GridAI Technologies EBITDA Margin % Related Terms
GridAI Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GridAI Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRDX vs CELU, NRSN, ZIVO: EBITDA Margin % Comparison
For the Biotechnology subindustry, GridAI Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GridAI Technologies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GridAI Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GridAI Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GridAI Technologies (GRDX) has a EBITDA Margin % of -6,947.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GridAI Technologies and its competitors. According to the industry distribution chart, GridAI Technologies ranks #887 out of 944 companies in the Biotechnology industry, placing it in the top 94%.
Is GridAI Technologies' EBITDA Margin % too high?
GridAI Technologies' current EBITDA Margin % is -6,947.37%. Based on the distribution chart, GridAI Technologies ranks #887 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GridAI Technologies has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does GridAI Technologies' EBITDA Margin % compare to CELU and NRSN?
According to the Biotechnology industry distribution chart, GridAI Technologies ranks #887 out of 944 companies for EBITDA Margin %. This places GridAI Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GridAI Technologies and its competitors. GridAI Technologies's current EBITDA Margin % is -6,947.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GridAI Technologies stock overvalued right now?
GridAI Technologies (GRDX) has a current EBITDA Margin % of -6,947.37%. The current EBITDA Margin % is -6,947.37%. GridAI Technologies' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GridAI Technologies (GRDX), the current EBITDA Margin % is -6,947.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
26GF Score
Get the complete analysis for GRDX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDX has been successfully added to your 
